(2-hydrazinylpyridin-4-yl)methanol | 1051928-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2-hydrazinylpyridin-4-yl)methanol
• CAS: 1051928-99-4
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: XOUATPSHXHXABS-UHFFFAOYSA-N

物化性质

• 沸点：
  337.5±34.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  71.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4,4-三氟-1-(2-呋喃基)-1,3-丁二酮 、 (2-hydrazinylpyridin-4-yl)methanol 在 溶剂黄146 作用下， 以51%的产率得到(2-(5-(furan-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-4-yl)methanol
  参考文献：
  名称：

  N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)

  摘要：

  A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.075
• 作为产物：
  描述：

  (2-氯吡啶-4-基)甲醇 在 肼 作用下， 以 异丙醇 为溶剂， 反应 24.0h， 以26%的产率得到(2-hydrazinylpyridin-4-yl)methanol
  参考文献：
  名称：

  WO2008/104077

  摘要：

  公开号：

文献信息

• [EN] HUMAN PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE HUMAINE
  申请人：BIOCRYST PHARM INC

  公开号：WO2015134998A1

  公开（公告）日：2015-09-11

  Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

  本文披露的是公式（I）的化合物及其药用盐。这些化合物是血浆激肽酶的抑制剂。还提供了包含本发明化合物的药物组合物，以及涉及使用这些化合物和组合物治疗和预防由不需要的血浆激肽酶活性特征的疾病和症状的方法。
• Reversible constitutional switching between macrocycles and polymers induced by shape change in a dynamic covalent system
  作者：Sébastien Ulrich、Eric Buhler、Jean-Marie Lehn

  DOI：10.1039/b817261g

  日期：——

  the covalent reversible link. It was then demonstrated that the molecular shape state of the morphological switches induces a well-defined constitution through covalent self-assembly, and that the system can be steered, quantitatively and reversibly without significant fatigue, between two different constitutional states, respectively, polymeric and macrocyclic assemblies. The dynamic covalent polymeric

  我们在此报告形态学开关的发展，它是一种可用于构造动态化学（CDC）中以控制整个动态系统构造的新工具。设计并合成了形状明确但可切换的分子。它们在固体和溶液中的受约束的构象状态都被表征。金属离子的添加​​通过配位引起形状变化；固体和溶液中生成的形状也得到了充分研究。此类分子构成形态学转换，这意味着由于效应器触发的可控定义明确的形状变化，它们可以探索各种形状状态。然后通过形成可逆的亚胺键将这些形态转换整合到共价动态系统中。进行热力学和动力学分析以定量共价平衡并研究共价可逆连接的不稳定特征。然后证明了形态转换的分子形状状态通过共价自组装诱导了明确定义的结构，并且该系统可以在两个不同的结构状态（分别为聚合状态和聚合状态）之间定量，可逆地操纵，而不会产生明显的疲劳。大环程序集。通过DOSY NMR和小角中子散射（SANS）分析了动态共价聚合物组装体。他们的动力学行为随浓度和温度的变化得到了证明和表征。
• Amines as Small Molecule Inhibitors
  申请人：Wahhab Amal

  公开号：US20080280925A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. Said compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.

  本发明涉及一种具有以下公式（I）、公式（II）和公式（III）之一的化合物，以及它们的外消旋混合物、对映异构体、恒定异构体和互变异构体以及N-氧化物、水合物、溶剂物、药学上可接受的盐、前药和复合物，其作为蛋白质精氨酸甲基转移酶抑制剂。所述化合物作为PRMTs和/或CARM-I的抑制剂具有用途。本发明还涉及包含这些化合物的组合物和它们的使用方法。
• Amines as small molecule inhibitors
  申请人：MethylGene Inc.

  公开号：US08338437B2

  公开（公告）日：2012-12-25

  The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. The compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.

  本发明涉及一种化合物，其具有公式（I），公式（II）和公式（III）中选择的公式，以及它们的外消旋混合物，对映异构体，对映体和互变异构体以及N-氧化物，水合物，溶剂化物，药学上可接受的盐，前药和复合物，如本文所定义的，这些化合物可用作蛋白质精氨酸甲基转移酶的抑制剂和/或CARM-I。本发明还涉及包含这种化合物的组合物和使用它们的方法。
• Human plasma kallikrein inhibitors
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：US10329260B2

  公开（公告）日：2019-06-25

  Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

  公开了式 I 的化合物 及其药学上可接受的盐类。这些化合物是血浆激肽的抑制剂。此外，还公开了包含至少一种此类化合物的药物组合物，以及涉及使用这些化合物和组合物治疗和预防以不需要的血浆激肽活性为特征的疾病和病症的方法。